SCIENCE NEWS | Vaccine and IL-2 Improve Response, Survival in Patients with Advanced Melanoma A vaccine for advanced melanoma, supplemented by the immunotherapy drug interleukin-2, has shown promise in one of the most comprehensive studies of the skin cancer vaccine’s effectiveness to date. [Press release from the University of South Florida discussing online prepublication in the New England Journal of Medicine]
Neuroscientists Map a New Target to Wipe Pain Away Researchers have discovered a peptide that short circuits a pathway for chronic pain. [Press release from Indiana University School of Medicine discussing online prepublication in Nature] Stem Cell Treatment to Prevent Leukemia Returning Is a Step Closer Researchers have identified a way of eliminating leukemic stem cells, which could in the future lead to new treatments that may enable complete remission for leukemia patients. [Press release from King’s College London discussing online prepublication in Cell Stem Cell] Gene Therapy Flunks Limb Ischemia Test A large Phase III clinical trial failed to confirm the beneficial effects of a promising gene therapy for critical limb ischemia that had been seen in early studies, investigators reported. [Press release from Medpage Today discussing online prepublication in The Lancet]
Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team reported. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in the Journal of Clinical Oncology]
New Drugs Target Delay of Huntington’s Symptoms Chemists have synthesized a new form of DNA, one that can begin to be used to create new gene regulation therapies, for the prevention or treatment of diseases such as cancer. [Press release from McMaster University discussing online prepublication in Nature Chemical Biology]
Scientists Reactivate Immune Cells Exhausted by Chronic HIV Scientists have demonstrated why certain immune cells chronically exposed to HIV shut down, and how they can be reactivated. [Press release from the National Institute of Allergy and Infectious Diseases discussing online prepublication in the Journal of Clinical Investigation]
A New Form of DNA Chemists have synthesized a new form of DNA for the prevention or treatment of diseases such as cancer. [Press release from Northwestern University discussing online prepublication in the Journal of the American Chemical Society]
Minivectors Renew Gene Therapy Hopes for Lung Treatments Minivectorâ„¢ DNA survive the stress of aerosolization and can carry gene therapy deep into the lungs, said researchers. [Press release from Baylor College of Medicine discussing online prepublication in Gene Therapy]
Stem Cells From Fat Used To Repair Skull Defects Stem cells derived from abdominal fat are a potentially valuable new approach to repairing skull defects after brain surgery, according to a study. [Press release from Medical News Today discussing online prepublication in Neurosurgery]
Potential New Drug Candidate Found for Alzheimer’s Disease Researchers have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid in the brains of animal models for Alzheimer’s disease, but also results in a substantial improvement in memory deficit. [Press release from the University of California, San Diego discussing online prepublication in the Journal of Alzheimer’s Disease]
Stem Cells: Gene Repair Tool for Stem Cells Researchers engineered an adenovirus that efficiently fixes mutated portions of the lamin A (LMNA) gene in stem cells created by reprogramming patients’ cells. [Nature Press Release] Argos Therapeutics´ Arcelisâ„¢ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination with Sunitinib Demonstrates Strong Immunologic Response that Correlates to Improved Clinical Outcomes Argos Therapeutics announced that its Arcelisâ„¢ immunotherapy for the treatment of RCC, AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. [Argos Therapeutics discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology] Study Finds Vaccine Extends Recurrent GBM Survival Rates by Two to Three Times Cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate. [Press release from University Hospitals discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology]
Combination Antibody Therapy Shows Promise in Metastatic Melanoma A duo of drugs can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a Phase I clinical trial. [Press release from ScienceDaily discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology]
Agennix Announces New Data from Talactoferrin Phase II Trials in Non-Small Cell Lung Cancer and in Severe Sepsis Agennix AG announced that new data from Phase II trials in non-small cell lung cancer and in severe sepsis demonstrating the activity and tolerability of talactoferrin, an oral immunotherapy with antibacterial properties, were presented. [Press release from Agennix AG discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology]
Vical Presents Positive Correlation Between Response and Survival at ASCO for Completed Allovectin® Melanoma Trials Vical Incorporated announced results from new statistical analyses of data from three previously completed clinical trials of the company’s Allovectin® immunotherapy in patients with metastatic melanoma, showing with strong positive correlation that responders lived significantly longer than nonresponders. [Press release from Vical Incorporated discussing research presented at the 2011 American Society of Clinical Oncology] Stem Cell Treatment May Offer Option for Broken Bones that Don’t Heal Researchers have shown in an animal study that transplantation of adult stem cells enriched with a bone-regenerating hormone can help mend bone fractures that are not healing properly. [Press release from the University of North Carolina at Chapel Hill School of Medicine discussing research presented at The Endocrine Society’s 93rd Annual Meeting]
Aastrom Demonstrates Statistically Significant Improvement in Time to First Occurrence of Treatment Failure at 12 Months in RESTORE-CLI Clinical Trial Aastrom Biosciences, Inc. announced that the final analysis of data from all 86 randomized patients in the RESTORE-CLI trial showed that the trial met its primary safety and efficacy endpoints, demonstrating a statistically significant improvement in the time to first occurrence of treatment failure at 12 months. [Aastrom Biosciences, Inc. Press Release]
Targeted Therapy Promising For Cancer Patients Customizing targeted therapies to each tumor’s molecular characteristics may be more effective for some types of cancer, according to research. [The University of Texas MD Anderson Cancer Center Press Release] Diabetic Drug Could Help Prevent the Spread of Cancer A protein activated by certain drugs already approved for treating Type II diabetes may slow or stop the spread of breast tumors. [Queen’s University Press Release]
EmailAddress&u=http://www.stemsoft.com/Forms/Stemlab_Video.aspx?utm_source=ctn%26utm_medium=banner%26utm_campaign=STEMSOFTStemLab_645x110&t=(Archive)CTN12.22ii”> | POLICY | Bracing Tour of China Leaves E.U. Science Chief Impressed Visiting China for the first time, Europe’s top research official, Máire Geoghegan-Quinn, admitted that she was bowled over by how quickly the rising power is muscling up its R&D. [European Union’s Commissioner for Research, Innovation, and Science, European Union]
NC House Backs Drug-Maker Lawsuit Protections North Carolina (NC) lawmakers have approved legislation that would shield drug companies from state liability suits. The state’s House voted 86-32 to grant FDA-approved drugs immunity from lawsuits, putting the new law in the hands of the state Senate. [North Carolina House, United States] House Trims Homeland Security Science Spending Next year’s budget for science and technology at the U.S. Department of Homeland Security would be drastically downsized under a spending bill passed by the House of Representatives. [House of Representatives, United States] | BUSINESS | PR 2011-05-30 Immune Collaboration with Stirling and Zodiac Immune Network Ltd. advises that it has entered into a conditional agreement with Stirling Products Limited and Zodiac Capital Limited with regard to an improved formulation of Immunoxel/Dzherelo recently developed and clinically tested by the Company. [Immune Network Ltd. Press Release]
MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene’s AAVLP Platform MediGene AG and The Johns Hopkins University have agreed to collaborate in the field of AAVLP vaccine technology. [MediGene AG Press Release] Bristol, Roche Team Up on Melanoma Study Bristol-Myers Squibb and Roche Holding AG said they would evaluate their respective cancer drugs as a potential combination therapy for metastatic melanoma. [Reuters] $1.1 Million Donation for Pioneering Stem Cell MS Trial Multiple Sclerosis (MS) research is to benefit from a $1.1 million donation to further a pioneering bone marrow stem cell trial, which has been shown to have possible benefits for the treatment of the disease. [University of Bristol Press Release] Cells Do Talk to One Another, but the Question Remains How The National Science Foundation’s Advances in Biological Informatics program area has awarded a three-year, $1.12 million research grant to three Virginia Tech researchers with expertise in systems biology and tissue engineering: T.M. Murali of computer science, Padma Rajagopalan of chemical engineering, and Rich Helm of biochemistry. [Virginia Tech Press Release] MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences MaRS Innovation and GlaxoSmithKline Inc. announced a new development fund – the GSK-MaRS Innovation Fund – that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centers, hospitals and universities derived from the MI membership. [MaRS Innovation Press Release] UTSA and Southwest Research Institute to Collaborate on Biomedical Research The University of Texas at San Antonio (UTSA) Office of the Vice President for Research and Southwest Research Institute (SwRI) announce an award of $200,000 in FY 2013 Connect program funding to UTSA Peter T. Flawn Professor of Biomedical Engineering Rena Bizios and SwRI Senior Research Scientists Vicky Poenitzsch and Xingguo Cheng for their collaborative research proposal, “Novel Scaffolds for Tendon-Ligament Regeneration and Tissue Engineering Applications.” [The University of Texas at San Antonio Press Release] Clavis Pharma Receives Government Grant to Develop hENT1 Biomarker Assay for Targeted Therapy of AML Patients Clavis Pharma ASA announced that it has been awarded a grant from The Research Council of Norway of up to NOK $14 mill (USD $2.5 mill) for the development of a flow cytometry method for the detection and quantification of human Equilibrative Nucleoside Transporter (hENT1) in patients suffering from acute myeloid leukemia (AML). [Clavis Pharma ASA Press Release]
YM BioSciences Announces Orphan Drug Designation for JAK1/JAK2 Inhibitor CYT387 in Europe YM BioSciences Inc. announced that it has received positive opinions from the Committee for Orphan Medicinal Products of the European Commission to grant Orphan Medicinal Product Designation to its JAK1/JAK2 inhibitor, CYT387, for the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis. [YM BioSciences Inc. Press Release]
SymBio Announces Korea NDA Approval of Bendamustine Hydrochloride (SyB L-0501) SymBio Pharmaceuticals Limited announced that the Korea Food and Drug Administration approved bendamustine HCI (SyB L-0501) for the treatment of patients with chronic lymphocytic leukemia and multiple myeloma on May 31, 2011. [SymBio Pharmaceuticals Limited Press Release]
Consortium Opens Landmark Personalized Medicine Children’s Cancer Trial The Neuroblastoma and Medulloblastoma Translational Research Consortium announced the opening of a first-of-its-kind genomic-based clinical trial to treat and study pediatric cancer – specifically relapsed and refractory neuroblastoma. [Van Andel Institute Press Relase] Researcher Leads National Study of Novel Approach to Treat Triple-Negative Breast Cancer A multicenter clinical trial will evaluate a new approach to treat triple-negative breast cancer. The study will help researchers determine if an experimental drug, entinostat, can reprogram tumor cells to express a protein called estrogen receptor to make them sensitive to hormone therapy. [University of Maryland Press Release] Pioneering Stem Cell Bandage Receives UK Approval for Clinical Trial The world’s first clinical trial for the treatment of patients with torn meniscal cartilage has received approval from the UK regulatory agency, the MHRA, to commence. The Phase I trial will treat meniscal tear patients with a cell bandage product, seeded with the patient’s own, expanded, stem cells. [University of Bristol Press Release]
Tekmira Expands Oncology Pipeline with RNAi Therapeutic Targeting Novel Cancer Genes WEE1 and CSN5 Tekmira Pharmaceuticals Corporation announced that it has secured licenses from Alnylam Pharmaceuticals, Inc. under its InterfeRxâ„¢ program to develop a new RNAi therapeutic targeting two validated oncology targets: WEE1 and CSN5. [Tekmira Pharmaceuticals Corporation Press Release] | |
|
|